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Abstract 
         Background  and  objectives:  Although  inflammatory  changes  are  found  throughout  the 
airways of patients with chronic bronchitis (CB), the mechanisms of the pathogenesis of CB are 
still unclear. The aim of this study was to investigate airways inflammation in patients with and 
without an exacerbation of CB. Granulocyte macrophage-colony stimulating factor (GM-CSF) 
levels in serum and bronchoalveolar lavage
 (BAL) fluid were assayed. Materials and methods: 
40 CB patients and 10 never smoking, age and sex matched controls were studied. 20 of the CB 
patients were studied under baseline conditions (B), and 20 during an exacerbation (E) of CB. 
Bronchoscopy and bronchoalveolar lavage (BAL) with cytological analysis were performed for 
7  males  from  CB(E)  group,  and  6  males  from  CB(B)  group.  The  levels  of  GM-CSF  were 
determined in sera and in BAL supernatants by a solid phase enzyme immunoassay. Results: 
There was high significant elevation of serum GM-CSF in both CB (E) and CB(B) groups in 
comparison with the control group (P<0.0001 & P=0.002 respectively). Both serum and BAL 
GM-CSF levels were elevated in CB(E) group in comparison with CB(B) group (P=0.0001 & 
P=0.009 respectively). Also there was significant elevation of BAL neutrophils, eosinophils and 
lymphocytes in CB(E) in comparison with CB(B) (P<0.05, P<0.01 and P<0.01 respectively). 
There was  only significant  positive  correlation between  BAL  GM-CSF and  BAL  neutrophils 
count in CB(E) group, while no significant results were detected in CB(B) group. Conclusion: 
During  exacerbations  of  CB  there  were  changes  in  the  cell  populations  in  BAL  of  patients 
consistent with a recruitment of polymorphonuclear leucocytes, eosinophils and lymphocytes in 
the airway lumen. These recruited different inflammatory cells could work together
 toward the 
production of  airway  abnormalities and  lung  destruction. The  locally  elevated levels  of  BAL 
GM-CSF  might  be  a  cause  and  /or  a  result  suggesting  a  role  for  this  cytokine  in  the 
inflammatory processes of chronic bronchitis. The elevated levels of serum GM-CSF in chronic 
bronchitis may be due to the interference of other cytokines, microenvironmental factors in bone 
marrow and/or other factors.  
 
Introduction 
         Chronic  bronchitis  (CB)  is  a  clinical 
syndrome  defined  by  cough  and  chronic 
sputum production
 occurring  on  most  days 
of  the  month  for  at  least  3 months  a  year 
during
  the  two years  prior  to  the  study. 
Sputum  is  defined  as  expectorated  lower 
respiratory tract secretions and is composed 
of fluid and cellular components, including 
macrophages, bronchial epithelial cells  and 
inflammatory cells (Seatta et al, 1997). The 
major risk factor for the development
 of CB 
is  cigarette  smoking,  but  the  precise 
pathogenetic
 mechanism  of  chronic  sputum 
production  is  still  unknown.  CB  is 
associated  with  intermittent  exacerbations
 
(chronic  bronchitis  with  acute 
exacerbations  [CB(E)])  that  present
  with 
worsening  of  the  chronic  symptoms  of 
productive  cough  and  dyspnea.
  These 
exacerbations cause considerable morbidity 
and  in  patients
  with  concomitant  airway 
obstruction  are  major  causes  of
 mortality. 
CB(E)  can  have  one  or  more  of  several 
different
  etiologies  including  viral 
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infections  and  atypical  bacterial  infections 
(Sethi et al, 2000). 
The development of CB seems to be related 
to  inflammatory  changes  of  airway 
structure. However, the cause and the exact 
location and type of these changes resulting 
in  altered  airway  function  are  not  known. 
Mucosal  inflammation  is  characterized  by 
the  recruitment  of  granulocytes, 
macrophages  and  lymphocytes  as  well  as 
by  the  shedding  of  epithelial  cells  (Linden 
et al, 1990). 
         Granulocyte  macrophage  colony 
stimulating  factor  (GM-CSF)  is  a  small 
glycoprotein  produced  by  monocytes/ 
macrophages,  endothelial  cells,  and 
epithelial  cells.  This
  cytokine  stimulates 
proliferation  and  maturation  of  monocytic
 
and  polymorphonuclear  leukocytes  and 
increases  the  effector  functions
 of  mature 
leukocytes (Lau et al, 1996). Human GM-
CSF is a 127 amino acid polypeptide with a 
molecular  weight  of  18-22  KD.  The 
biological effects of GM-CSF are mediated 
following binding to a high affinity receptor 
on  mature  neutrophils,  macrophages  and 
eosinophils. Macrophages also secrete GM-
CSF in  response to  stimulation with
 lipop-
olysaccharides  (LPS)  and  other  immune 
effectors.  In  humans,  GM-CSF
  concen-
trations  in  serum  and  alveolar  lining  have 
been reported
 to be in the low pg/ml range. 
The  concentration  of  GM-CSF  in  bronch-
oalveolar
  lavage  (BAL)  fluid  can  be 
increased  in  some  inflammatory  lung
 con-
ditions such as sarcoidosis, asthma, chronic 
obstructive  pulmonary
  disease,  and  usual 
interstitial  pneumonitis  (Walker  et  al, 
1994).  
         Bronchoscopy and  BAL can  be  used 
to  investigate  the  airways  inflammation 
associated  with  CB.  Visual  inspection  of 
the  airways  provides  presumptive  evidence 
of  inflammation  (Thompson  and  Rennard, 
1990).  BAL  provides  a  direct  sample  that 
can  be  compared  with  cellular  and 
immunologic  components  in  the  vascular 
circulation.  Thus,  the  recovery  of  BAL 
fluid  and  its  components  involved  directly 
with  CB  process  permits  a  much  more 
detailed  assessment  of  new  cellular 
mediators and cytokines participating in the 
pathologic  process  (Reynolds  2000). 
Abundant  neutrophils  and  mononuclear 
cells  (lymphocytes)  with  a  few  of 
eosinophils  are  observed  in  BAL  fluids 
from  chronic  bronchitis  patients  (Shimura, 
1999).  BAL  findings  differ  from  sputum 
findings  because  the
  former  technique 
samples  mainly  the  alveolar  compartment 
whereas
  the  latter  samples  primarily  the 
bronchial  compartment.  In  general,
 sputum 
is  richer  in  neutrophils.
  However,  there 
seems to be good agreement in the number 
of  eosinophils
 between  sputum,  BAL,  and 
biopsies (Maestrelli et al, 1995). The results 
of both
 sputum induction and BAL seem to 
be  affected  by  the  procedure
 itself.  When 
repeating  sputum  induction
  at  daily 
intervals,  the  proportion  of  neutrophils  in 
induced  sputum
  increases.  Similarly,  the 
number of neutrophils in BAL
 is  increased 
7 and  24 h  after  performing  a  BAL. 
Although
 these findings do not detract from 
the  value  of  these  procedures,
  they  do 
highlight the  fact that  neutrophil  migration 
to the airway
 lumen can be induced by the 
sampling
 procedure (Kips et al, 1995). 
 
Subjects, materials and methods  
         This  study  was  conducted  in  The 
Chest  Department,  of  Alzahraa  University 
hospital.  The  study  included  40  chronic 
bronchitis patients (CB) and 10 apparently 
healthy  never  smoking,  age  and  sex 
matched  controls.  20  of  the  CB  patients 
were studied under baseline conditions [CB 
(B)].  They  were  16  males  &  4  females, 
their ages ranged from 40-58 years. And 20 
CB  patients  during  an  exacerbation  of 
bronchitis [CB (E)]. They were 18 males & 
2  females,  their  ages  ranged  from  42-55 
years.  All  of  the  patients  examined  in  the 
present  study  had  smoked  cigarettes  at 
some point in their life. Currently smoking 
or  patients  who  had  smoked  within
  6 
months  of  assessment  were  excluded. 
Complete  clinical  examination,  postro-
anterior  plain  X  rays  and  Zeihl  Nelson`s 
stain  were  done  to  all  studied  subjects. 
Sputum  inspection  of  studied  patients  was 
characteristically viscous.  When held up to 
the light, pale green or white streaks could 
often  be  seen  in  the  mucus.  Patients` 
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illustrated in table (1). Exacerbations were 
diagnosed  according  to
  criteria  from 
Anthonisen and colleagues. The patient had
 
to  have  experienced  any  two  of  the  three 
major  symptoms-increase
  in  dyspnea, 
sputum  purulence,  and  increased  sputum 
volume in order
 to be classified as having a 
CB(E) (Anthonisen et al, 1987). 
         Bronchoscopy  and  BAL  with 
cytological  analysis  were  performed  for  7 
male patients from the CB(E) group before 
treatment  and  6  male  patients  from  the 
CB(B)  group.  All  studied  cases  revealed 
presumptive  evidences  of  inflammation  by 
visual inspection.  
Bronchoalveolar  lavage:  BAL  was 
performed according to the ERS guidelines 
using  a  flexible  fibreoptic
  bronchoscope 
(Olympus,  P-20  Olympus,  Tokyo,  Japan) 
after local
 anaesthesia  of  the  upper  airway 
with  2%  lidocaine.  The  bronchoscope
 was 
wedged  into  one  of  the  segmental  bronchi 
of  the  right  middle
 lobe  for  lavage  and  an 
aliquot  of  50 ml  sterile  saline  at  body
 
temperature  was  instilled  through  the 
bronchoscope.  The  fluid
  was  immediately 
retrieved  by  gentle  suction  using  a  sterile 
syringe.
 The entire procedure of instillation 
and  retrieval  was  repeated
 three  times  (  a 
total  of  150  ml  saline).  BAL  fluid  was 
placed  on  ice  and  processed  within 
10 minutes  after  recovery.  It  was  filtered 
through  gauze.  BAL  fluid  was  centrifuged 
at 500g for  5 minutes at  4°C. The  protein 
content  of  the  BAL  fluid  supernatant
 was 
measured  chemically  by  auto-analyzer 
model  Hitachi  902.  A  part  of  BAL  fluid 
supernatant
 was stored at -20 for GM-CSF 
assay. The cell pellet was suspended in PBS 
(phosphate  buffered  saline)  and  counted 
using automated cell counter model Coulter 
T-660  (Rutgers  et  al,  2000).
  Drops  of 
suspended  cell  pellet  were  spread  onto  a 
glass
 slide.  The  resulting
 slides  were  dried, 
fixed,  and  then  stained  using  Leishman`s 
stain. A manual
 differential cell counts were 
determined  from  300 cells  using  a
 
photomicroscope (De Brauwer et al, 2002). 
         The  levels  of  GM-CSF  were 
determined in sera and in BAL supernatants 
by  a  solid  phase  enzyme  immunoassay 
(ELISA) using Predicta Genzyme kit. Test 
samples  or  standards  were  added  to  test 
wells  containing  immobilized  mouse 
monoclonal  antibody  to  human  GM-CSF 
and incubated. The wells were washed and 
a  direct-labled  HRP-conjugated  polyclonal 
antibody  to  GM-CSF  was  added  which 
bound to captured GM-CSF during incuba-
tion.  After  washing,  a  substrate  solution 
was  added  producing  a  blue  colour.  The 
reaction  was  stopped  and  the  blue  colour 
turned  yellow.  The  intensity  of  the  colour 
was directly proportional to the amount of 
GM-CSF present. The absorbance was read 
at  450  nm  and  a  standard  curve  was 
constructed to quantitate GM-CSF concen-
trations in the samples.    
 
Statistical analysis 
    Data  were  expressed  as  mean  ±  SD. 
Student’s  t  test  used  to  detect  the 
difference.  Spearman  correlation  was 
tested,  a  probability  (P)  value  <0.05  was 
considered-significant.  
 
Results 
 
Table (1): Criteria of chronic bronchitis (CB) groups. 
 
           Inclusion criteria                   Exclusion criteria 
1- The presence of chronic bronchitis.  1- A history of asthma
 or atopy. 
2-Absence of asthma
 or bronchiectasis.  2-Use of chronic oral or parenteral steroids. 
3-  Ability  to
  comply  with  monthly                 
clinic visits. 
3-  History  of  bronchiectasis,  lung  cancer,  TB,  or        
congestive heart
 failure. 
 4-Absence  of  immunosuppression  or                 
other life-threatening
 illness. 
4-Current  smoking  or  history  of  having  smoked           
within
 6 months of assessment. 
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Table (2): Comparison between chronic bronchitis (E) and control groups. 
 
     CB(E) (n=20) 
    mean ± SD 
     Control (n=10) 
       mean ± SD 
    P 
 
   Sig 
Serum GM-CSF  pg/ml       6.6 ± 3.2      1.1 ± 0.4  0.0001  HS 
CB: chronic bronchitis         E: exacerbation      Sig: significance     HS: highly significant 
  There was high significant elevation of serum GM-CSF in CB (E) group in comparison 
with the control group (table 2). 
 
Table (3): Comparison between chronic bronchitis (B) and control groups. 
 
       CB(B) (n=20) 
        mean ± SD 
     Control (n=10) 
       mean ± SD 
    P 
 
   Sig 
Serum GM-CSF  pg/ml       2.2 ± 0.9      1.1 ± 0.4  0.002       S 
CB: chronic bronchitis         B: basal condition       Sig: significance       S: significant 
  There was significant elevation of serum GM-CSF in CB (B) group in comparison with 
the control group (table 3). 
 
Table (4): Comparison between CB(E) and CB(B) groups.  
 
  CB (E) BAL (n=7)  
     mean ± SD 
CB(B) BAL (n=6)    
     mean ± SD 
    P 
 
   Sig 
Serum GM-CSF  pg/ml  6.6 ± 3.2    2.2 ± 0.9    0.0001  HS 
BAL   GM-CSF  pg/ml  18.2 ± 2.0  10.0 ± 3.4    0.009  HS 
BAL  neutrophil     x10
3/ml    3.7± 0.7    1.6 ± 0.4  <0.05    S 
BAL  eosinophils   x10
3/ml      1.5 ± 0.1    0.7 ± 0.1  <0.01    S 
BAL  lymphocytes x10
3/ml      13.5 ± 2.1    5.9 ± 1.1  <0.01    S 
BAL  total protein  gm/dl  0.2 ± 0.03  0.19 ± 0.01  >0.05  NS 
CB: chronic bronchitis        E: exacerbation           B: basal condition       Sig: significance 
BAL: bronchoalveolar lavage     HS: highly significant      S: significant    NS: non significant 
  The chronic bronchitis during exacerbation group showed high significant elevation of 
both  serum  GM-CSF  &  BAL  GM-CSF  with  only  significant  elevation  of  BAL  neutrophils, 
eosinophils and lymphocytes in  comparison with the chronic  bronchitis under basal  condition 
group (table 4). 
 
Table  (5):  correlation  between  BAL  GM-CSF  and  other  studied  parameters  in  CB(E) 
group. 
 
          r          P  significance 
Serum GM-CSF       pg/ml       0.37      >0.05       NS 
BAL neutrophils   x10
3/ml       0.6      <0.05          S 
BAL eosinophils   x10
3/ml       0.1      >0.05       NS 
BAL lymphocytes x10
3/ml       0.15      >0.05       NS 
  There  was  only  significant  positive  correlation  between  BAL  GM-CSF  and  BAL 
neutrophils count in CB(E) group (table 5). 
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Table  (6):  correlation  between  BAL  GM-CSF  and  other  studied  parameters  in  CB(B) 
group. 
 
          r          P  significance 
Serum GM-CSF       pg/ml         0.45      >0.05       NS 
BAL neutrophils   x10
3/ml         0.3      >0.05       NS 
BAL eosinophils   x10
3/ml         0.1      >0.05       NS 
BAL lymphocytes x10
3/ml         0.1      >0.05       NS 
  No significant correlation was detected between BAL GM-CSF and any of the studied 
parameters in CB(B) group (table 6). 
 
Discussion 
         Chronic bronchitis is characterized by 
inflammatory  changes  in  the  bronchial 
tissue  and  by  recurrent  bronchitis 
exacerbations  (Balbi  et  al,  1997).  Acute 
exacerbation  of  chronic  bronchitis  is  an 
important  disease  affecting  millions  of 
patients with CB. The use of antibiotics in 
such  patients  is  controversial,  as  the 
etiology  of  acute  exacerbation  is  complex, 
including  inhalation  of  environmental 
irritants,  discontinuation  of  medications, 
deviation  from  diet,  viral  infections  and 
atypical  bacterial  infections.  Although  the 
use  of  antibiotics  in  patients  with  acute 
exacerbation  has  been  reported  to  be 
beneficial, it is clear that not every episode 
of  acute  exacerbation  needs  antimicrobial 
therapy.  Furthermore,  injudicious  use  of 
antibiotics  has  led  to  increasing  bacterial 
resistance,  resulting  in  ineffectiveness  of 
commonly  used  antibiotics 
(Watanakunakorn 2000). 
         In  the  present  study  there  was 
significant  elevation  of  serum  GM-CSF  in 
both CB(E) and CB(B) in comparison with 
the  control  group  (P=0.0001  and  P=0.002 
respectively).  Also  serum  GM-CSF  was 
significantly  elevated  in  CB(E)  when 
compared  with  CB(B)  group  (P=0.0001). 
Balbi  et  al  (1997)  reported  that  patients 
with  chronic  bronchitis,  as  a  whole,  had 
significantly increased levels  of BAL  GM-
CSF  compared  to  control  subjects,  and 
similar levels of serum GM-CSF. Also they 
found  that  both  serum  and  BAL  levels  of 
GM-CSF  were  markedly  increased  in 
chronic  bronchitic  patients  with  an 
exacerbation,  as  compared  with  patients 
under  baseline  conditions.  The  data  of  the 
present  study  showed  that  BAL  GM-CSF 
was  insignificantly  correlated  with  serum 
GM-CSF  in  both  CB  groups  (P<0.05). 
These results might indicate that BAL GM-
CSF  was  locally  produced  by  the 
inflammatory  cells  within  the  airways  and 
lung  parenchyma  rather  than  being 
passively  transferred  from  the  serum. 
Erduran  et  al  (1997)  found  that  the  mean 
serum  GM-CSF  levels  in  patients  with 
acute  pulmonary  infection  (non-repeaters) 
were significantly higher than patients with 
recurrent  pulmonary  infections  (repeaters) 
in the acute period of infection, but serum 
GM-CSF  levels  of  both  groups  were  not 
different in the recovery period. In addition, 
they  reported  that  the  serum  GM-CSF 
levels  of  both  repeaters  and  non-repeaters 
in the acute period of infection were higher 
than  those  in  the  recovery  period.  The 
elevated  levels  of  serum  GM-CSF  in  both 
CB(E)  and  CB(B)  in  the  present  study  in 
comparison to the control may be due to the 
interference  of  other  cytokines, 
microenvironmental factors in bone marrow 
and/or other factors.  
         There is increasing evidence that CB 
is  associated  with  chronic  inflammation  in
 
the airways and lung parenchyma. The data 
of  the  present  study  revealed  high 
significant elevation of BAL GM-CSF with 
only  significant  elevation  of  BAL 
neutrophils, eosinophils and lymphocytes in 
CB(E)  group  when  compared  with  CB(B) 
group  (P=0.009,  P<0.05,  P<0.01  and 
P<0.01  respectively).  These  data  might 
indicate  that,  during  exacerbations  of  CB 
there  were  changes  in  the  cell  populations 
in  BAL  of  patients  consistent  with  a 
recruitment  of  polymorphonuclear  leucoc-
ytes  in  the  airway  lumen.  The  increased 
levels of GM-CSF would suggest a role for 
this cytokine in the inflammatory processes Granulocyte macrophage-colony stimulating…….. 
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of chronic bronchitis. Rinsho (1999) found 
that abundant  neutrophils and  lymphocytes 
with a few of eosinophils were observed in 
BAL  fluids  from  chronic  bronchitis 
patients,  while  abundant  neutrophils  and 
macrophages were seen in BAL fluids from 
emphysema  patients.  Seatta  et  al  (1997) 
reported  that  the  location  of  neutrophils 
within  the  bronchial  glands  is
 crucial  for 
activation of the secretory function of gland 
cells,
  and  therefore  for  induction  of  the 
chronic sputum production in
 subjects with 
chronic bronchitis. 
         Aaron  et  al  (2001)  reported  that 
patients  with  clinically
  stable  CB  were 
known  to  have  increased  numbers  of 
neutrophils
  and  macrophages  in  their 
sputum  and  BAL  fluid
 relative  to  normal 
subjects,  suggesting  that  neutrophil 
recruitment and activation
 might play a role 
in  the  pathogenesis  of  chronic  airflow 
disease. 
         Di Stefano et al (1996) found that the 
inflammatory changes  in  the  large  airways 
of  subjects  with  CB  had  shown  a 
predominance
 of lymphocytes in the airway 
wall  and  a  predominance
 of  neutrophils  in 
the airway lumen. This discrepancy
 had led 
to  the  hypothesis  that  the  inflammation  in 
the  lumen  may
  differ  from  that  in  the 
bronchial  wall  in  patients  with  CB.  The 
results  of  the  study  done  by  Saetta  et  al 
(1997)  showed  an  increased  number
  of 
neutrophils  in  the  bronchial  glands  of 
subjects with CB, providing evidence for a 
neutrophilia  not  only  in  the
 airway  lumen 
but also in the airway wall of these subjects, 
contributing
 to a better understanding of the 
apparent  discrepancy  between
 luminal  and 
parenchymal findings in this disease.
  
         Cosio  and  Guerassimov  (1999) 
findings in CB with exacerbations were  of 
interest.  They  reported  that  large  numbers 
of  neutrophils  and  eosinophils  were  found 
in  both  sputum  and  bronchial
  biopsies. 
Since  exacerbations  were  most  often 
secondary
 to  an  infection  so  this  was  not 
surprising.  They  explained  that,  possibly 
the
 earliest  inflammatory  reaction  involves 
the  neutrophil,  followed
  by  the  alveolar 
macrophages in all the epithelial surfaces of 
the lung. These cells
 would in time damage 
epithelial  cells  and  the  interstitial  protein
 
structures  (elastin,  collagenase,  proteo-
glycans,  etc.).  These
  proteins  could  be 
processed  by  dendritic  cells  and 
macrophages  into  peptides  with  antigenic 
potential  that  could  be  recognized  by  T 
cells  initiating  T  cell  activation  and 
proliferation.
 These activated T cells, could 
recruit  other  cells  such  as  neutrophils  and 
even  eosinophils  to  the  site  of 
inflammation.  Thus,  all
  these  different 
inflammatory  cells  could  work  together
 
toward  the  production  of  airway 
abnormalities and lung destruction. Wells et 
al  (1998)  reported  that  neutrophils  were 
linked  to  the  morphological  extent  of 
disease  in  patients  with  lung  lesion  and 
eosinophils  were  more  closely  linked  to 
functional impairment than neutrophils. 
         In  the  present  study  there  was  only 
significant  positive  correlation  between 
BAL GM-CSF and BAL neutrophils count 
in CB during exacerbation group (P<0.05). 
On  the  other  hand  no  significant  results 
were detected in CB under basal conditions. 
These results might indicate that BAL GM-
CSF could play a role in the recruitment of 
neutrophils in the large airways of subjects 
with CB during exacerbations.  
 
Conclusion 
During  exacerbations  of  chronic  bronchitis 
there are changes in the cell populations in 
bronchoalveolar  lavage  of  patients 
consistent with a recruitment of polymorph-
onuclear  leucocytes,  eosinophils  and 
lymphocytes  in  the  airway  lumen.  The 
locally  elevated  levels  of  BAL  GM-CSF 
might be a cause and /or a result suggesting 
a role for this cytokine in the inflammatory 
processes  of  chronic  bronchitis.  Recruited 
neutrophils  and  eosinophils  may  release 
increased  amounts  of  inflammatory  medi-
ators  capable  of  damaging  the  bronchial 
tissue.  Further  studies  to  clarify  whether 
GM-CSF participates in the pathogenesis of 
neutrophil
 mediated  lung  diseases
 such  as 
acute  respiratory  distress  syndrome  and 
collagen vascular
 disease are recommended.  
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بحملا ةريبكلا تمهتلملا تيلخلا ةرمعتسمل طشنملا لماعلا ثايىتسم  ىف تب
نمزملا ىبعشلا باهتللإا ىضرم ىف ىبعشلا ىلصيىحلا ليسغلا لئاس  
 
د . سيرلا ىملح ىنم  * د و . ذمحأ ذيس راصتنإ **  
خيئبيٌلهاو خيليِيوكلإا بيجىهىصبجها ًٌظق  * خيرذصها ضازًلأا و  ** دبِجها تط خيوك -  
زهسلأا خعًبج .  
 
          اىهها دازٌٌها ملاخ خيثبهزهإ دازيغر دىجو ًَ يغزهبث  ًجعشها ةبهزهلإا ًضزً ًف خيئ
ٍإف ًَشٌها   خيليُبليً   رىطر   خحضاو زيغ ماشر لا ضزٌها اذه .  
   ددحبلا اذدده :  ًجعددشها ةبددهزهلإا ًددضزً ًددف خدديئاىهها دازددٌٌها ةبددهزهإ  ددحف ًددهإ شددحجها اذددهي
داذزددإث ةىحدصٌها و ةىحدصً زديغها ًَشدٌها  .  حزٌعزددظٌه عدشٌِها ندًبعها دبيىزدظً صبديق قهذددكو
خددٌهزوٌها خدديوخها    خددججحٌها حزدديجلها ( ى ج -   ا ص ك  )  ًوددصيىحها نيددظغها نئبددط و نددصٌها َددً نددك ًددف
ًجعشها .  
 ددحبلا برددق و داىددم :  ًددو  خددطارذها ذددٌر ٤װ    و ًَشددٌها ًجعددشها ةبددهزهلإا ًددضزً َددً װװ    َددً
خطثبدض خد ىٌكٌك ضِدكها و زدٌعها ًدف َينفاىدزٌها و َيخذدزها يهه قجظي يه َيذها ءبحصلأا  .  ٍبدك و
װװ    ةبهزهلإا ًضزً ًَ ٍبك بٌِيث حزنزظً خهبح ًف ًَشٌها ًجعشها װװ   داذزددإ خدهبح ًف يهًِ  .  ذدقو
 ًجعددد ًوددصيىح نيددظغ و ًجعددد ربددشًِ نددٌ  يددر ( م ا ة  )  دذددعه يىددوخ ندديوحر تددً ۷    مبددجر َددً
 و داذزدلإا خهبح خ ىٌكً ٦   رازنزطلإا خ ىٌكً مبجر ًَ  . ى ج دبيىزدظً صبيق ير قهذك -  ا ص ك
بينها خططاىث م ا ة ىفط ًفو نصٌهبىف خجوصها خئيهوه ًٌيشُلإا ً بٌِها ص .  
جئاتنلا : ى ج ًف بًبه ب بفررإ جئبزِها دزهظأ -    ةبدهزهلإا ًز ىدٌكً ًَ نك ًف نصٌها ًف ا ص ك
خطثبدةها خد ىٌكٌهبث يهزُربدنً ذدِ  حذزدشٌها و حزنزظٌها ًَشٌها ًجعشها  .  بد بفررإ كبدِه ٍبدك قهذدك
ى ج يىزددظً ًددف -   دد ىٌكً ًددف م ا ة و نددصٌها َددً نددك ًددف ا ص ك  بددهزُربنً ذددِ  داذزدددلإا خ
حزنزددظٌها خدد ىٌكٌهبث  .  و خيددةٌحها بدديلاخها و خددهدبعزٌها بدديلاخها ًددف خددًبه حدبدديس كبددِه ٍبددك بددةيأ
حزنزدظٌها خد ىٌكٌهبث يهزُربنً ذِ  داذزدلإا خ ىٌكً م ا ة ًف خيوبفٌيوها بيلاخها  .  شدحجها زدهظأ و
ى ج َيددث خددًبه خددججىً خددقلا  -    خددهدبعزٌها بدديلاخها دذدد  و ا ص ك  خدد ىٌكً ًددف م ا ة نئبددط ًددف
حذزشٌها ًَشٌها ًجعشها ةبهزهلإا .  
جاتنتسلإا :  ًدف ًجعدشها ًودصيىحها نيدظغها ًدف بيلاخها ىاىقأ ًف دازيغر كبِه ٍأ شحجها ًَ جزِزظُ
 ىذددها دازددك ذدديِكر تددً ًددشٌزي زددييغزها اذدده ٍأ و داذزدددلإا ءبددِصأ ًَشددٌها ًجعددشها ةبددهزهلإا ًددضزً
 حاىِها مبلدأ حدذعزً ءبةيجها خديئاىهها دازدٌٌها فيىكر ًف خيوبفٌيوها بيلاخها و خيةٌحها بيلاخها و  .
 ًددف دبثازطددضإ ساذددحىه بددعً نددٌعر ٍأ َددلًٌ حذددِكٌها و خددفوزخٌها خدديثبهزهلإا بدديلاخها ّذدده ٍأ و
خئزوه زيًذر و خيئاىهها دازٌٌها  . ى ج يىزدظً ًدف خيعدضىٌها حدبديشها ٍأ بدٌك -    م ا ة ًدف ا ص ك
 ٍىددلي ذددق ًددضزٌها ءلاءدده  دبددثبهزهإ ًددف يىددوخها كزددحٌها اذددهه ارود قهذددث بددحززنً خددكيزُ وأ تجددط
خددًِشٌها خدديئاىهها تعددشها  . ى ج حدبدديس ٍىددلر ذددق و -    ًجعددشها ةبددهزهلإا ًددضزً نددصً ًددف ا ص ك
يزخأ نًاى  وأ يشعها عبخُ ًف خيئيث نًاى  وأ يزخأ بيلاخ دبكزحً نخذزه خكيزُ ًَشٌها .      
 